Mid Cap Volatile Stocks: Ubiquiti Networks (NASDAQ:UBNT), Qunar Cayman Islands (NASDAQ:QUNR), Criteo (NASDAQ:CRTO), Intercept Pharmaceuticals (NASDAQ:ICPT)

Stock analysts at Macquarie initiated coverage on shares of Ubiquiti Networks Inc (NASDAQ:UBNT) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Ubiquiti Networks Inc (NASDAQ:UBNT) stock performance was -10.22% in last session and finished the day at $44.18. Traded volume was 2.87million shares in the last session and the average volume of the stock remained 1.34million shares. Ubiquiti Networks Inc (NASDAQ:UBNT) insider ownership is 0.50%.

Macquarie assumed coverage on shares of Qunar Cayman Islands Ltd (NASDAQ:QUNR) in a report issued on Monday, TheFlyOnTheWall.com reports. The firm issued a neutral rating and a $30.00 target price on the stock. Qunar Cayman Islands Ltd (NASDAQ:QUNR) dropped -7.67 percent to $26.83 Wednesday on volume of 1.22million shares. The intra-day range of the stock was $26.76 to $29.66. Qunar Cayman Islands Ltd (NASDAQ:QUNR) has a market capitalization of $3.02billion.

Criteo SA (ADR) (NASDAQ:CRTO) has set the price of its 5,250,000 American Depository Shares (ADSs), each representing one of Criteo SA (ADR) (NASDAQ:CRTO)’s ordinary shares, to the public at $45.00 per share. Criteo SA (ADR) (NASDAQ:CRTO)’s stock on Mar 26, 2014 reported a decrease of -12.34% to the closing price of $40.34. Its fifty two weeks range is $28.27 -$60.95. The total market capitalization recorded $2.32billion. The overall volume in the last trading session was 730.1K shares. In its share capital, CRTO has 53.28million outstanding shares.

In March 2014, the officers of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) named in the table below entered into pre-arranged stock trading plans pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). On Wednesday, shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) dropped -8.11% to close the day at $322.32. Company return on investment (ROI) is -47.90% and its monthly performance is recorded as -14.97%. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) quarterly revenue growth is 405.52%.